NASDAQ:RGNX

REGENXBIO Competitors

$34.51
-1.36 (-3.79 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$34.07
Now: $34.51
$36.60
50-Day Range
$33.61
MA: $37.83
$42.51
52-Week Range
$25.92
Now: $34.51
$50.26
Volume213,824 shs
Average Volume460,977 shs
Market Capitalization$1.47 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.28

Competitors

REGENXBIO (NASDAQ:RGNX) Vs. ADPT, CBPO, ALLO, BEAM, IOVA, and SWTX

Should you be buying RGNX stock or one of its competitors? Companies in the industry of "biological products, except diagnostic" are considered alternatives and competitors to REGENXBIO, including Adaptive Biotechnologies (ADPT), China Biologic Products (CBPO), Allogene Therapeutics (ALLO), Beam Therapeutics (BEAM), Iovance Biotherapeutics (IOVA), and SpringWorks Therapeutics (SWTX).

REGENXBIO (NASDAQ:RGNX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Earnings and Valuation

This table compares REGENXBIO and Adaptive Biotechnologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$35.23 million41.64$-94,730,000.00($3.26)-10.59
Adaptive Biotechnologies$85.07 million68.78$-68,610,000.00($1.01)-41.61

Adaptive Biotechnologies has higher revenue and earnings than REGENXBIO. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 80.8% of Adaptive Biotechnologies shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 22.2% of Adaptive Biotechnologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares REGENXBIO and Adaptive Biotechnologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
REGENXBIO-63.13%-21.73%-18.74%
Adaptive Biotechnologies-132.32%-20.15%-13.09%

Risk and Volatility

REGENXBIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 0.35, meaning that its stock price is 65% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for REGENXBIO and Adaptive Biotechnologies, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
REGENXBIO02512.88
Adaptive Biotechnologies02402.67

REGENXBIO presently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Adaptive Biotechnologies has a consensus price target of $61.40, suggesting a potential upside of 46.71%. Given REGENXBIO's stronger consensus rating and higher probable upside, analysts clearly believe REGENXBIO is more favorable than Adaptive Biotechnologies.

Summary

Adaptive Biotechnologies beats REGENXBIO on 8 of the 15 factors compared between the two stocks.

REGENXBIO (NASDAQ:RGNX) and China Biologic Products (NASDAQ:CBPO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, analyst recommendations, dividends, valuation, institutional ownership and profitability.

Risk and Volatility

REGENXBIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Comparatively, China Biologic Products has a beta of 0.47, meaning that its stock price is 53% less volatile than the S&P 500.

Earnings and Valuation

This table compares REGENXBIO and China Biologic Products' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$35.23 million41.64$-94,730,000.00($3.26)-10.59
China Biologic Products$503.70 million9.24$138.81 million$4.2827.63

China Biologic Products has higher revenue and earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than China Biologic Products, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares REGENXBIO and China Biologic Products' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
REGENXBIO-63.13%-21.73%-18.74%
China Biologic Products27.43%8.32%7.64%

Insider & Institutional Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 34.8% of China Biologic Products shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 2.7% of China Biologic Products shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for REGENXBIO and China Biologic Products, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
REGENXBIO02512.88
China Biologic Products0000N/A

REGENXBIO presently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Given REGENXBIO's higher probable upside, analysts clearly believe REGENXBIO is more favorable than China Biologic Products.

REGENXBIO (NASDAQ:RGNX) and Allogene Therapeutics (NASDAQ:ALLO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Risk and Volatility

REGENXBIO has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. Comparatively, Allogene Therapeutics has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Valuation and Earnings

This table compares REGENXBIO and Allogene Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$35.23 million41.64$-94,730,000.00($3.26)-10.59
Allogene TherapeuticsN/AN/A$-184,590,000.00($1.83)-17.77

REGENXBIO has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares REGENXBIO and Allogene Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
REGENXBIO-63.13%-21.73%-18.74%
Allogene TherapeuticsN/A-27.59%-24.97%

Institutional & Insider Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 59.9% of Allogene Therapeutics shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 31.3% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for REGENXBIO and Allogene Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
REGENXBIO02512.88
Allogene Therapeutics031302.81

REGENXBIO currently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Allogene Therapeutics has a consensus price target of $52.0833, suggesting a potential upside of 60.55%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Allogene Therapeutics.

Summary

REGENXBIO beats Allogene Therapeutics on 9 of the 13 factors compared between the two stocks.

REGENXBIO (NASDAQ:RGNX) and Beam Therapeutics (NASDAQ:BEAM) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends and risk.

Institutional & Insider Ownership

75.2% of REGENXBIO shares are held by institutional investors. Comparatively, 49.8% of Beam Therapeutics shares are held by institutional investors. 14.1% of REGENXBIO shares are held by insiders. Comparatively, 0.7% of Beam Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a breakdown of recent recommendations for REGENXBIO and Beam Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
REGENXBIO02512.88
Beam Therapeutics03302.50

REGENXBIO currently has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Beam Therapeutics has a consensus price target of $96.00, suggesting a potential upside of 31.18%. Given REGENXBIO's stronger consensus rating and higher probable upside, equities research analysts clearly believe REGENXBIO is more favorable than Beam Therapeutics.

Valuation and Earnings

This table compares REGENXBIO and Beam Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$35.23 million41.64$-94,730,000.00($3.26)-10.59
Beam Therapeutics$20,000.00227,047.22$-78,330,000.00($14.05)-5.17

Beam Therapeutics has lower revenue, but higher earnings than REGENXBIO. REGENXBIO is trading at a lower price-to-earnings ratio than Beam Therapeutics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares REGENXBIO and Beam Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
REGENXBIO-63.13%-21.73%-18.74%
Beam Therapeutics-529,075.00%-103.41%-48.05%

Summary

REGENXBIO beats Beam Therapeutics on 11 of the 14 factors compared between the two stocks.

Iovance Biotherapeutics (NASDAQ:IOVA) and REGENXBIO (NASDAQ:RGNX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk and dividends.

Valuation & Earnings

This table compares Iovance Biotherapeutics and REGENXBIO's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Iovance BiotherapeuticsN/AN/A$-197,560,000.00($1.59)-18.96
REGENXBIO$35.23 million41.64$-94,730,000.00($3.26)-10.59

REGENXBIO has higher revenue and earnings than Iovance Biotherapeutics. Iovance Biotherapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Iovance Biotherapeutics and REGENXBIO, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Iovance Biotherapeutics011002.91
REGENXBIO02512.88

Iovance Biotherapeutics currently has a consensus price target of $50.50, suggesting a potential upside of 64.87%. REGENXBIO has a consensus price target of $62.50, suggesting a potential upside of 81.79%. Given REGENXBIO's higher probable upside, analysts plainly believe REGENXBIO is more favorable than Iovance Biotherapeutics.

Volatility and Risk

Iovance Biotherapeutics has a beta of 0.94, meaning that its stock price is 6% less volatile than the S&P 500. Comparatively, REGENXBIO has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500.

Institutional and Insider Ownership

94.6% of Iovance Biotherapeutics shares are owned by institutional investors. Comparatively, 75.2% of REGENXBIO shares are owned by institutional investors. 9.9% of Iovance Biotherapeutics shares are owned by company insiders. Comparatively, 14.1% of REGENXBIO shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Iovance Biotherapeutics and REGENXBIO's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Iovance BiotherapeuticsN/A-50.64%-45.64%
REGENXBIO-63.13%-21.73%-18.74%

Summary

REGENXBIO beats Iovance Biotherapeutics on 9 of the 14 factors compared between the two stocks.

REGENXBIO (NASDAQ:RGNX) and SpringWorks Therapeutics (NASDAQ:SWTX) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, valuation, earnings and profitability.

Valuation & Earnings

This table compares REGENXBIO and SpringWorks Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
REGENXBIO$35.23 million41.64$-94,730,000.00($3.26)-10.59
SpringWorks TherapeuticsN/AN/A$-58,310,000.00($3.55)-19.72

SpringWorks Therapeutics has lower revenue, but higher earnings than REGENXBIO. SpringWorks Therapeutics is trading at a lower price-to-earnings ratio than REGENXBIO, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and price targets for REGENXBIO and SpringWorks Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
REGENXBIO02512.88
SpringWorks Therapeutics00403.00

REGENXBIO presently has a consensus target price of $62.50, suggesting a potential upside of 81.79%. SpringWorks Therapeutics has a consensus target price of $95.20, suggesting a potential upside of 33.26%. Given REGENXBIO's higher probable upside, research analysts clearly believe REGENXBIO is more favorable than SpringWorks Therapeutics.

Risk and Volatility

REGENXBIO has a beta of 1.28, indicating that its share price is 28% more volatile than the S&P 500. Comparatively, SpringWorks Therapeutics has a beta of 0.92, indicating that its share price is 8% less volatile than the S&P 500.

Insider and Institutional Ownership

75.2% of REGENXBIO shares are owned by institutional investors. Comparatively, 76.3% of SpringWorks Therapeutics shares are owned by institutional investors. 14.1% of REGENXBIO shares are owned by insiders. Comparatively, 51.2% of SpringWorks Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares REGENXBIO and SpringWorks Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
REGENXBIO-63.13%-21.73%-18.74%
SpringWorks TherapeuticsN/A-24.48%-23.58%

Summary

REGENXBIO beats SpringWorks Therapeutics on 9 of the 14 factors compared between the two stocks.


REGENXBIO Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Adaptive Biotechnologies logo
ADPT
Adaptive Biotechnologies
1.6$42.03-2.4%$5.85 billion$85.07 million-44.24
China Biologic Products logo
CBPO
China Biologic Products
0.8$118.26-0.2%$4.65 billion$503.70 million33.03
Allogene Therapeutics logo
ALLO
Allogene Therapeutics
1.3$32.51-1.1%$4.57 billionN/A-15.26
Beam Therapeutics logo
BEAM
Beam Therapeutics
1.3$72.69-1.5%$4.54 billion$20,000.00-5.17
Iovance Biotherapeutics logo
IOVA
Iovance Biotherapeutics
1.7$30.14-1.0%$4.43 billionN/A-15.70Analyst Report
Increase in Short Interest
Gap Down
SpringWorks Therapeutics logo
SWTX
SpringWorks Therapeutics
1.8$70.01-5.1%$3.43 billionN/A-40.24Insider Selling
NanoString Technologies logo
NSTG
NanoString Technologies
1.3$73.01-1.6%$3.25 billion$125.57 million-42.70Insider Selling
Revolution Medicines logo
RVMD
Revolution Medicines
1.7$40.32-3.1%$2.96 billion$50.04 million0.00
Relay Therapeutics logo
RLAY
Relay Therapeutics
1.8$32.60-3.5%$2.95 billionN/A0.00News Coverage
Vericel logo
VCEL
Vericel
1.1$58.62-1.1%$2.70 billion$117.85 million-5,862,000.00Increase in Short Interest
Editas Medicine logo
EDIT
Editas Medicine
1.6$34.67-18.2%$2.34 billion$20.53 million-19.93Analyst Report
Gap Up
Sorrento Therapeutics logo
SRNE
Sorrento Therapeutics
1.3$7.49-0.7%$2.10 billion$31.43 million-5.13Gap Up
BioCryst Pharmaceuticals logo
BCRX
BioCryst Pharmaceuticals
1.3$11.24-0.9%$2.00 billion$48.83 million-14.79Analyst Report
Rubius Therapeutics logo
RUBY
Rubius Therapeutics
1.6$24.30-1.0%$1.97 billionN/A-11.36Decrease in Short Interest
Gap Up
bluebird bio logo
BLUE
bluebird bio
1.8$28.28-5.1%$1.90 billion$44.67 million-2.58
NantKwest logo
NK
NantKwest
1.1$17.26-4.7%$1.89 billion$40,000.00-24.31
Kymera Therapeutics logo
KYMR
Kymera Therapeutics
1.3$38.66-0.3%$1.73 billionN/A0.00Analyst Report
Increase in Short Interest
Gap Up
Krystal Biotech logo
KRYS
Krystal Biotech
1.5$77.33-0.9%$1.72 billionN/A-52.25
Sangamo Therapeutics logo
SGMO
Sangamo Therapeutics
1.3$11.48-2.5%$1.65 billion$102.43 million-19.13
Immunovant logo
IMVT
Immunovant
1.8$15.42-3.0%$1.51 billionN/A-11.95Increase in Short Interest
News Coverage
Alector logo
ALEC
Alector
1.3$18.48-4.9%$1.47 billion$21.22 million-8.29
Replimune Group logo
REPL
Replimune Group
1.5$30.23-2.8%$1.45 billionN/A-17.08
AlloVir logo
ALVR
AlloVir
1.4$22.08-2.4%$1.44 billionN/A0.00Increase in Short Interest
Translate Bio logo
TBIO
Translate Bio
1.6$18.84-4.5%$1.42 billion$7.80 million-17.61
C4 Therapeutics logo
CCCC
C4 Therapeutics
1.4$32.55-1.1%$1.40 billionN/A0.00Increase in Short Interest
Forma Therapeutics logo
FMTX
Forma Therapeutics
1.8$25.65-10.4%$1.21 billion$100.56 million0.00Increase in Short Interest
Mesoblast logo
MESO
Mesoblast
1.4$8.89-1.2%$1.17 billion$32.16 million-10.10Analyst Upgrade
Decrease in Short Interest
Atara Biotherapeutics logo
ATRA
Atara Biotherapeutics
1.4$13.24-5.3%$1.17 billionN/A-2.87
Ocugen logo
OCGN
Ocugen
1.1$5.89-4.4%$1.16 billionN/A-3.98Increase in Short Interest
Cortexyme logo
CRTX
Cortexyme
1.3$39.50-2.1%$1.14 billionN/A-16.46Analyst Downgrade
Curis logo
CRIS
Curis
1.3$11.37-7.4%$1.12 billion$10 million-13.87Increase in Short Interest
Scholar Rock logo
SRRK
Scholar Rock
1.5$30.77-0.4%$1.05 billion$20.49 million-12.77Increase in Short Interest
Coherus BioSciences logo
CHRS
Coherus BioSciences
1.4$14.39-1.0%$1.05 billion$356.07 million7.05
Vaxcyte logo
PCVX
Vaxcyte
1.7$18.22-7.0%$935.20 millionN/A0.00Increase in Short Interest
Black Diamond Therapeutics logo
BDTX
Black Diamond Therapeutics
1.6$25.86-2.5%$934.53 millionN/A-4.27Insider Selling
Increase in Short Interest
Sutro Biopharma logo
STRO
Sutro Biopharma
1.3$20.01-6.7%$918.30 million$42.74 million-222.33Increase in Short Interest
Analyst Revision
News Coverage
Gap Up
TCR2 Therapeutics logo
TCRR
TCR2 Therapeutics
1.6$24.17-1.9%$904.23 millionN/A-9.99Increase in Short Interest
Analyst Revision
Taysha Gene Therapies logo
TSHA
Taysha Gene Therapies
1.8$23.86-4.4%$900.98 millionN/A0.00Analyst Report
Analyst Revision
News Coverage
Adverum Biotechnologies logo
ADVM
Adverum Biotechnologies
1.5$8.86-6.1%$866.47 million$250,000.00-6.98Analyst Upgrade
News Coverage
Gap Up
Passage Bio logo
PASG
Passage Bio
1.8$15.88-8.3%$854.84 millionN/A0.00Increase in Short Interest
Aligos Therapeutics logo
ALGS
Aligos Therapeutics
1.5$21.71-2.7%$850.59 millionN/A0.00Lockup Expiration
Gap Down
Cellectis logo
CLLS
Cellectis
1.3$19.40-0.5%$829.93 million$22.99 million-10.32
Aerie Pharmaceuticals logo
AERI
Aerie Pharmaceuticals
1.7$17.25-3.9%$809.32 million$69.89 million-4.12
Adaptimmune Therapeutics logo
ADAP
Adaptimmune Therapeutics
1.5$4.93-2.2%$766.45 million$1.12 million-4.98Increase in Short Interest
Gap Up
Orchard Therapeutics logo
ORTX
Orchard Therapeutics
1.6$6.02-5.3%$744.64 million$2.51 million-3.65
DBV Technologies logo
DBVT
DBV Technologies
1.0$6.11-2.3%$686.71 million$14.75 million-2.62Increase in Short Interest
Inhibrx logo
INBX
Inhibrx
1.6$18.03-16.4%$680.60 millionN/A0.00Decrease in Short Interest
Gap Up
Harpoon Therapeutics logo
HARP
Harpoon Therapeutics
1.5$20.00-1.3%$648.22 million$5.78 million-9.39Insider Selling
Unusual Options Activity
Analyst Revision
Vaxart logo
VXRT
Vaxart
1.3$5.35-1.5%$630.05 million$9.86 million-9.07
MeiraGTx logo
MGTX
MeiraGTx
1.4$14.08-1.6%$623.24 million$13.29 million-9.99
This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.